Nothing Special   »   [go: up one dir, main page]

BRPI0813513A2 - Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer - Google Patents

Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer

Info

Publication number
BRPI0813513A2
BRPI0813513A2 BRPI0813513-4A2A BRPI0813513A BRPI0813513A2 BR PI0813513 A2 BRPI0813513 A2 BR PI0813513A2 BR PI0813513 A BRPI0813513 A BR PI0813513A BR PI0813513 A2 BRPI0813513 A2 BR PI0813513A2
Authority
BR
Brazil
Prior art keywords
integrine
links
cancer treatment
medicinal product
specific therapy
Prior art date
Application number
BRPI0813513-4A2A
Other languages
English (en)
Inventor
Stefan Krueger
Simon Goodman
Original Assignee
Merck Patent Gmbh
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Merck Patent Gmbh filed Critical Merck Patent Gmbh
Publication of BRPI0813513A2 publication Critical patent/BRPI0813513A2/pt

Links

Classifications

    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00Medicinal preparations containing inorganic active ingredients
    • A61K33/24Heavy metals; Compounds thereof
    • A61K33/243Platinum; Compounds thereof
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/02Antineoplastic agents specific for leukemia
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • A61P35/04Antineoplastic agents specific for metastasis
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Organic Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Inorganic Chemistry (AREA)
  • Hematology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
BRPI0813513-4A2A 2007-07-18 2008-07-17 Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer BRPI0813513A2 (pt)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
EP07014070 2007-07-18
PCT/EP2008/005831 WO2009010287A2 (en) 2007-07-18 2008-07-17 Specific therapy and medicament using integrin ligands for treating cancer

Publications (1)

Publication Number Publication Date
BRPI0813513A2 true BRPI0813513A2 (pt) 2015-01-06

Family

ID=39402737

Family Applications (2)

Application Number Title Priority Date Filing Date
BRPI0806596-9A BRPI0806596A2 (pt) 2007-01-18 2008-01-17 medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer
BRPI0813513-4A2A BRPI0813513A2 (pt) 2007-07-18 2008-07-17 Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer

Family Applications Before (1)

Application Number Title Priority Date Filing Date
BRPI0806596-9A BRPI0806596A2 (pt) 2007-01-18 2008-01-17 medicamento e terapia especÍfica usando-se ligantes de integrina para o tratamento de cÂncer

Country Status (19)

Country Link
US (2) US20100069302A1 (pt)
EP (4) EP2441464B1 (pt)
JP (3) JP2010516645A (pt)
KR (2) KR20090108713A (pt)
CN (2) CN101588812A (pt)
AU (2) AU2008207095B2 (pt)
BR (2) BRPI0806596A2 (pt)
CA (2) CA2675813A1 (pt)
CO (1) CO6382135A2 (pt)
DK (1) DK2101805T3 (pt)
EA (2) EA017864B1 (pt)
EC (1) ECSP109969A (pt)
ES (2) ES2399159T3 (pt)
IL (1) IL199696A0 (pt)
MX (1) MX2009007597A (pt)
PL (1) PL2101805T3 (pt)
PT (1) PT2101805E (pt)
WO (2) WO2008087025A2 (pt)
ZA (1) ZA200905703B (pt)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
PT2101805E (pt) * 2007-01-18 2013-01-31 Merck Patent Gmbh Terapia específica e medicamento usando ligandos integrina para tratar o cancro
US20110230423A1 (en) * 2008-11-20 2011-09-22 Martin Andreas Picard Therapy and medicament using integrin ligands for treating cancer
MX2011012491A (es) * 2009-05-25 2011-12-14 Merck Patent Gmbh Administracion continua de cilengitida en tratamientos contra el cancer.
CA2775601C (en) 2009-09-28 2017-10-03 Qilu Pharmaceutical Co., Ltd 4-(substituted anilino)-quinazoline derivatives useful as tyrosine kinase inhibitors
WO2011146819A2 (en) * 2010-05-20 2011-11-24 Dmd Therapies, Llc METHODS AND COMPOSITIONS FOR TREATMENT NF-κB-MEDIATED AND α7 INTEGRIN-SUPPRESSED DISEASES
SG11201504392XA (en) * 2012-12-07 2015-07-30 Baxter Int Anti-mif antibody cell migration assay
WO2014205179A1 (en) * 2013-06-21 2014-12-24 The General Hospital Corporation Ribonucleotide reductase inhibitors sensitize tumor cells to dna damaging agents
KR101579054B1 (ko) * 2014-03-26 2015-12-21 한국원자력의학원 포도필로톡신 아세테이트를 유효 성분으로 포함하는 방사선치료 증진제
EP3194972B1 (en) * 2014-09-17 2021-04-14 Merck Patent GmbH A method of treating bone metastasis diseases, medicaments therefore, and a method of predicting the clinical outcome of treating bone metastasis diseases
WO2016067010A1 (en) * 2014-10-30 2016-05-06 Big Dna Ltd Combination therapy
EP3207937A1 (en) 2016-02-17 2017-08-23 Royal College of Surgeons in Ireland A method of treating or preventing sepsis
CN105906692A (zh) * 2016-03-11 2016-08-31 李书鹏 cRGD-厄洛替尼缀合物及其制备方法
GB2554333A (en) * 2016-04-26 2018-04-04 Big Dna Ltd Combination therapy
US20200271654A1 (en) * 2017-02-06 2020-08-27 Expression Pathology, Inc. Quantifying MGMT Protein For Optimal Cancer Therapy
WO2022157336A1 (en) 2021-01-22 2022-07-28 Royal College Of Surgeons In Ireland Treatment of coronavirus

Family Cites Families (87)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US701446A (en) 1901-12-30 1902-06-03 Lewis W Wooten Cotton-chopper.
US4342566A (en) 1980-02-22 1982-08-03 Scripps Clinic & Research Foundation Solid phase anti-C3 assay for detection of immune complexes
US4474893A (en) 1981-07-01 1984-10-02 The University of Texas System Cancer Center Recombinant monoclonal antibodies
US5260291A (en) 1981-08-24 1993-11-09 Cancer Research Campaign Technology Limited Tetrazine derivatives
US4661111A (en) 1982-08-04 1987-04-28 La Jolla Cancer Research Foundation Polypeptide
US4792525A (en) 1982-08-04 1988-12-20 La Jolla Cancer Research Foundation Tetrapeptide
US4589881A (en) 1982-08-04 1986-05-20 La Jolla Cancer Research Foundation Polypeptide
US4614517A (en) 1982-08-04 1986-09-30 La Jolla Cancer Research Foundation Tetrapeptide
US4578079A (en) 1982-08-04 1986-03-25 La Jolla Cancer Research Foundation Tetrapeptide
US4517686A (en) 1982-08-04 1985-05-21 La Jolla Cancer Research Foundation Polypeptide
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
US5225539A (en) 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
CA2062795A1 (en) 1989-06-29 1990-12-30 Michael W. Fanger Bispecific reagents for aids therapy
WO1991003493A1 (en) 1989-08-29 1991-03-21 The University Of Southampton Bi-or trispecific (fab)3 or (fab)4 conjugates
AU667460B2 (en) 1990-10-05 1996-03-28 Medarex, Inc. Targeted immunostimulation with bispecific reagents
EP0563214A4 (en) 1990-12-04 1994-08-17 Wistar Inst Bifunctional antibodies and method of preparing same
US5571894A (en) 1991-02-05 1996-11-05 Ciba-Geigy Corporation Recombinant antibodies specific for a growth factor receptor
US5587458A (en) 1991-10-07 1996-12-24 Aronex Pharmaceuticals, Inc. Anti-erbB-2 antibodies, combinations thereof, and therapeutic and diagnostic uses thereof
US5932448A (en) 1991-11-29 1999-08-03 Protein Design Labs., Inc. Bispecific antibody heterodimers
EP1514934B1 (en) 1992-02-06 2008-12-31 Novartis Vaccines and Diagnostics, Inc. Biosynthetic binding protein for cancer marker
US5407804A (en) 1992-05-22 1995-04-18 Applied Genetics Inc. Assays for O6 -methylguanine-DNA methyltransferase
GB9224888D0 (en) 1992-11-27 1993-01-13 Univ Singapore Monoclonal antibody
DE69329974T2 (de) 1992-12-04 2001-07-19 Medical Research Council, London Multivalente und multispezifische bindungsproteine, deren herstellung und verwendung
US5753230A (en) 1994-03-18 1998-05-19 The Scripps Research Institute Methods and compositions useful for inhibition of angiogenesis
US5504101A (en) 1994-05-06 1996-04-02 Allelix Biopharmaceuticals, Inc. 5-HT-1D receptor ligands
ES2186720T3 (es) 1994-05-27 2003-05-16 Merck & Co Inc Composiciones para inhibir la reabsorcion osea mediada por osteoclastos.
PL318199A1 (en) 1994-06-29 1997-05-26 Smithkline Beecham Corp Antagonists of vitronectin receptors
JPH10504807A (ja) 1994-06-29 1998-05-12 スミスクライン・ビーチャム・コーポレイション ビトロネクチン受容体拮抗剤
IT1271688B (it) 1994-08-04 1997-06-04 Menarini Ricerche Sud Spa Molecole ibride per il trattamento antitumorale loro preparazione e loro uso in composizioni farmaceutiche
AU2989695A (en) * 1994-08-08 2000-03-07 Debiopharm S.A. Pharmaceutically stable oxaliplatinum preparation
US6008214A (en) 1994-08-22 1999-12-28 Smithkline Beecham Corporation Bicyclic compounds
WO1996026190A1 (en) 1995-02-22 1996-08-29 Smithkline Beecham Corporation Integrin receptor antagonists
US5780426A (en) 1995-06-07 1998-07-14 Ixsys, Incorporated Fivemer cyclic peptide inhibitors of diseases involving αv β3
JP3960482B2 (ja) 1995-06-29 2007-08-15 スミスクライン・ビーチャム・コーポレイション インテグリン受容体アンタゴニスト
DE19534177A1 (de) 1995-09-15 1997-03-20 Merck Patent Gmbh Cyclische Adhäsionsinhibitoren
KR19990076878A (ko) 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
KR19990076876A (ko) 1995-12-29 1999-10-25 스티븐 베네티아너 비트로넥틴 수용체 길항제
CZ203898A3 (cs) 1995-12-29 1999-03-17 Smithkline Beecham Corporation Antagonista vitronektinového receptoru, farmaceutický přípravek s jeho obsahem, způsob a použití
AP806A (en) 1996-03-20 2000-01-28 Aventis Pharma Sa Tricyclic compounds having activity specific for integrins, particularly avB3 integrins, method for preparing same, intermediates therefor, use of said compounds as drugs, and pharmaceutical compositions containing same.
US5925655A (en) 1996-04-10 1999-07-20 Merck & Co., Inc. αv β3 antagonists
ATE227268T1 (de) 1996-04-10 2002-11-15 Merck & Co Inc Alpha v beta 3 antagonisten
WO1997041844A1 (en) 1996-05-09 1997-11-13 Alcon Laboratories, Inc. Combinations of angiostatic compounds
BR9709514A (pt) * 1996-05-31 1999-08-10 Scripps Research Inst Processo e composições úteis para a inibição de angiogénese mediada por alfa beta
US5786146A (en) 1996-06-03 1998-07-28 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
US6017704A (en) 1996-06-03 2000-01-25 The Johns Hopkins University School Of Medicine Method of detection of methylated nucleic acid using agents which modify unmethylated cytosine and distinguishing modified methylated and non-methylated nucleic acids
AU724191B2 (en) 1996-08-29 2000-09-14 Merck & Co., Inc. Integrin antagonists
US5981546A (en) 1996-08-29 1999-11-09 Merck & Co., Inc. Integrin antagonists
WO1998015278A1 (en) 1996-10-07 1998-04-16 Smithkline Beecham Corporation Method for stimulating bone formation
US5919792A (en) 1996-10-30 1999-07-06 Merck & Co., Inc. Integrin antagonists
JP2001504456A (ja) 1996-10-30 2001-04-03 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
JP2001503060A (ja) 1996-10-30 2001-03-06 メルク エンド カンパニー インコーポレーテッド インテグリン拮抗薬
AU5596298A (en) 1996-12-09 1998-07-03 Cor Therapeutics, Inc. Integrin antagonists
DE19653647A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653645A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Vitronectin - Rezeptorantagonisten, deren Herstellung sowie deren Verwendung
DE19653646A1 (de) 1996-12-20 1998-06-25 Hoechst Ag Substituierte Purinderivate, Verfahren zu deren Herstellung, sie enthaltende Mittel und deren Verwendung
CO4920232A1 (es) 1997-01-08 2000-05-29 Smithkline Beecham Corp Acidos aceticos dibenzo [a,d] cicloheptano con actividad antagonista del receptor de vitronectin
WO1998031359A1 (en) 1997-01-17 1998-07-23 Merck & Co., Inc. Integrin antagonists
DK0979281T3 (da) 1997-05-02 2005-11-21 Genentech Inc Fremgangsmåde til fremstilling af multispecifikke antistoffer med heteromultimere og fælles bestanddele
CA2297910A1 (en) 1997-07-25 1999-02-04 Smithkline Beecham Corporation Vitronectin receptor antagonist
CA2298544A1 (en) 1997-08-04 1999-02-11 Smithkline Beecham Corporation Integrin receptor antagonists
CA2304117A1 (en) 1997-09-04 1999-03-11 Dirk A. Heerding Integrin receptor antagonists
PE122699A1 (es) 1997-09-19 2000-02-12 Smithkline Beecham Corp Antagonistas de receptores de vitronectina
FR2768734B1 (fr) 1997-09-24 2000-01-28 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
AU9577498A (en) 1997-09-24 1999-04-12 Smithkline Beecham Corporation Vitronectin receptor antagonist
IL135188A0 (en) 1997-09-24 2001-05-20 Smithkline Beecham Corp Vitronectin receptor antagonist
FR2768736B1 (fr) 1997-09-24 2000-05-26 Roussel Uclaf Nouveaux composes tricycliques, leur procede de preparation et les intermediaires de ce procede, leur application a titre de medicaments et les compositions pharmaceutiques les renfermant
US6017926A (en) 1997-12-17 2000-01-25 Merck & Co., Inc. Integrin receptor antagonists
AU741769B2 (en) 1997-12-17 2001-12-06 Merck Sharp & Dohme Corp. Integrin receptor antagonists
CA2315370A1 (en) 1997-12-17 1999-06-24 Merck & Co., Inc. Integrin receptor antagonists
NZ504893A (en) 1997-12-17 2002-10-25 Merck & Co Inc 5, 6, 7, 8-Tetrahydro-[1,8]-naphthyridin-2-yl derivatives useful as integrin receptor antagonists
US6048861A (en) 1997-12-17 2000-04-11 Merck & Co., Inc. Integrin receptor antagonists
ATE299023T1 (de) 1997-12-17 2005-07-15 Merck & Co Inc Integrinrezeptor antagonisten
EP1049718B1 (en) 1998-01-23 2006-04-05 MERCK PATENT GmbH Use of the antibody 271.14d9.f8 (dsm acc2331) to inhibit in vitro alphavbeta6-integrin attachment to fibronectin
WO2000006169A1 (en) 1998-07-29 2000-02-10 Merck & Co., Inc. Integrin receptor antagonists
EP1105389A4 (en) 1998-08-13 2001-10-17 Merck & Co Inc INTEGRIN RECEPTOR ANTAGONISTS
DE19842415A1 (de) 1998-09-16 2000-03-23 Merck Patent Gmbh Pharmazeutische Zubereitung
BR9916518A (pt) * 1998-12-23 2002-01-29 Searle & Co Método para tratar ou prevenir um distúrbio de neoplasia em um mamìfero em necessidade de tal tratamento ou prevenção, e, combinação compreendendo um inibidor de ciclooxigenase-2 e um ou mais agentes anti-neoplásticos
BR0011108A (pt) 1999-06-02 2002-03-19 Merck & Co Inc Composto, composição farmacêutica, e, processos de eliciar um efeito antagonizante do receptor da integrina, de tratamento ou prevenção da osteoporose, de tratamento ou prevenção de uma condição mediada por antagonismo de um receptor de integrina, de inibição da reabsorção óssea em um mamìfero em necessidade do mesmo, e de tratamento do desenvolvimento tumoral
AU2001261724A1 (en) * 2000-05-19 2001-12-03 The Board Of Trustees Of The Leland Stanford Junior University Viral vectors useful in induction of humoral or cellular immunity
EP1328656A4 (en) * 2000-09-29 2005-09-14 Univ Johns Hopkins Med METHOD FOR PREDICTING THE CLINICAL RESPONSE TO CHEMOTHERAPY WITH ALKYLATING AGENTS
MXPA03006121A (es) * 2001-01-09 2003-09-10 Merck Patent Gmbh Terapia de combinacion usando inhibidores del receptor tirosin-cinasa e inhibidores de la angiogenesis.
JP4660067B2 (ja) * 2001-04-24 2011-03-30 メルク パテント ゲゼルシャフト ミット ベシュレンクテル ハフツング 抗血管新生剤とTNFαとを用いる組合せ療法
DE10228049A1 (de) * 2002-06-24 2004-01-15 Merck Patent Gmbh Flüssige Zubereitung enthaltend Oligopeptide
US20060084666A1 (en) * 2004-10-18 2006-04-20 Harari Paul M Combined treatment with radiation and an epidermal growth factor receptor kinase inhibitor
EA016817B1 (ru) * 2006-01-18 2012-07-30 Мерк Патент Гмбх Специфическая терапия, использующая интегриновые лиганды для лечения рака
PT2101805E (pt) * 2007-01-18 2013-01-31 Merck Patent Gmbh Terapia específica e medicamento usando ligandos integrina para tratar o cancro

Also Published As

Publication number Publication date
KR20100043242A (ko) 2010-04-28
AU2008207095A1 (en) 2008-07-24
ECSP109969A (es) 2010-03-31
WO2008087025A3 (en) 2008-12-11
EA200900912A1 (ru) 2009-12-30
ZA200905703B (en) 2010-05-26
DK2101805T3 (da) 2013-01-21
EA201000127A1 (ru) 2010-10-29
WO2009010287A2 (en) 2009-01-22
KR20090108713A (ko) 2009-10-16
AU2008277904A1 (en) 2009-01-22
EP2101805A2 (en) 2009-09-23
EP2101805B1 (en) 2012-11-07
MX2009007597A (es) 2009-07-22
ES2472450T3 (es) 2014-07-01
EP2578225A1 (en) 2013-04-10
JP2014015482A (ja) 2014-01-30
ES2399159T3 (es) 2013-03-26
WO2008087025A2 (en) 2008-07-24
CO6382135A2 (es) 2012-02-15
CA2693862A1 (en) 2009-01-22
PT2101805E (pt) 2013-01-31
AU2008207095B2 (en) 2013-08-29
CN101588812A (zh) 2009-11-25
CN101743013A (zh) 2010-06-16
EP2164506A2 (en) 2010-03-24
WO2009010287A3 (en) 2009-04-09
US20100190957A1 (en) 2010-07-29
BRPI0806596A2 (pt) 2013-07-23
JP2010516645A (ja) 2010-05-20
PL2101805T3 (pl) 2013-04-30
JP2010533665A (ja) 2010-10-28
IL199696A0 (en) 2010-04-15
EP2441464A1 (en) 2012-04-18
CA2675813A1 (en) 2008-07-24
EA017864B1 (ru) 2013-03-29
EP2441464B1 (en) 2014-04-09
US20100069302A1 (en) 2010-03-18

Similar Documents

Publication Publication Date Title
BRPI0813513A2 (pt) Terapia específica e medicamento usando ligantes de integrina para tratamento de câncer
BRPI0821660A2 (pt) Combinações de agentes terapêuticos para tratamento de câncer
BRPI0922771A2 (pt) agentes indutores de apoptose seletivos para bcl-2 para o tratamento de câncer e doenças imunes
BRPI0810816A2 (pt) Medicamento e métodos para tratar doenças auto-imune e câncer
BRPI0821779A2 (pt) tratamento terapêutico de câncer
BRPI0811589A2 (pt) Composição farmacêutica e método para tratar câncer
BR112012018947A2 (pt) composição farmacêutica para tratamento e\ou prevenção do cancêr
BRPI0810082A2 (pt) 3-imidazolil-indóis para o tratamento de doenças proliferativas
DK2121139T3 (da) Formulations for cancer treatment
EP2166837A4 (en) DRUG COMBINATION USEFUL FOR THE TREATMENT OF SKIN DISORDERS
BRPI0807987A2 (pt) Terapia de combinação para tratamento de distúrbios imunes.
EP2165715A4 (en) THERAPEUTIC AGENT FOR CANCER AND METHOD FOR TREATING CANCER
EP2046973A4 (en) METHODS OF IDENTIFYING, EVALUATING, AND TREATING PATIENTS SUBJECTED TO ANTICANCER THERAPY
BRPI0816712A2 (pt) terapia de intervalo para o tratamento de tinnitus
EP2125002A4 (en) TREATMENT OF SKIN CANCER
BRPI0821248A2 (pt) Inibidores de cinesina como fármacos terapêuticos para câncer
ZA200907245B (en) Phthalazinone derivatives and their use as medicament to treat cancer
IL205608A (en) History of s-triazole-1-ram-benzamide and their use in the preparation of pain medication
BRPI0820477A2 (pt) Compostos de benzodiazepinona úteis no tratamento de afecções da pele
EP2219448A4 (en) THERAPEUTIC COMPOUNDS AND THEIR USE IN THE TREATMENT OF DISEASES AND SUFFERINGS
BR112012031836A2 (pt) combinação farmacêutica para o tratamento da dor
EP2148675A4 (en) ANTI-CANCER FOR THE DIAGNOSIS AND TREATMENT OF CANCER
BRPI1010086A2 (pt) método e produtos para tratamento de doenças
BRPI1009448A2 (pt) combinações farmacêuticas compreendendo edea119/bay 869766 para o tratamento de cânceres específicos
BRPI0922367A2 (pt) enzastaurin para o tratamento de câncer

Legal Events

Date Code Title Description
B07D Technical examination (opinion) related to article 229 of industrial property law [chapter 7.4 patent gazette]
B08F Application dismissed because of non-payment of annual fees [chapter 8.6 patent gazette]

Free format text: REFERENTE AS 6A E 7A ANUIDADES.

B08K Patent lapsed as no evidence of payment of the annual fee has been furnished to inpi [chapter 8.11 patent gazette]

Free format text: EM VIRTUDE DO ARQUIVAMENTO PUBLICADO NA RPI 2343 DE 01-12-2015 E CONSIDERANDO AUSENCIA DE MANIFESTACAO DENTRO DOS PRAZOS LEGAIS, INFORMO QUE CABE SER MANTIDO O ARQUIVAMENTO DO PEDIDO DE PATENTE, CONFORME O DISPOSTO NO ARTIGO 12, DA RESOLUCAO 113/2013.